Tumor-specific cytolysis

"Tumor-specific cytolysis" does **not** refer to a single molecule, receptor, or canonical therapeutic target. Instead, it describes the process by which immune cells—primarily cytotoxic T lymphocytes (CTLs) and sometimes natural killer (NK) cells—specifically recognize and destroy tumor cells through mechanisms such as MHC-restricted antigen recognition and release of lytic granules[1][5][6]. This process is central to anti-tumor immunity and underlies many immunotherapeutic strategies but is not itself a molecular entity. The term may also be used in research contexts to describe the measurable outcome of immune effector function against tumors rather than a druggable target or protein. In summary, "tumor-specific cytolysis" is an important biological phenomenon in cancer immunology but should not be listed as a discrete molecular target for structured data purposes.

Other names

Tumor-specific cytolytic activityImmune cytolytic activityTumor-specific CTL response